Results 261 to 270 of about 579,778 (352)

The Influence of Sleep Breathing Disorder on Growth Hormone Secretion in Children with Tonsil Hypertrophy.

open access: bronze, 1998
Shintaro Chiba   +5 more
openalex   +2 more sources

Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel])
Vivek S. Purohit   +6 more
wiley   +1 more source

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE ...
Naïm Bouazza   +26 more
wiley   +1 more source

Medications, epilepsy and climate change: Added layers of complexity

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Climate change—the global crisis with pervasive health impacts—has adverse consequences for people with epilepsy (PWE) who have low quality of life due to poor seizure control, socioeconomic disadvantages and comorbidities. This review focuses on the potential effects of climate change on the pharmacological characteristics of antiseizure medications ...
Medine I. Gulcebi   +2 more
wiley   +1 more source

Contribution of Addictovigilance data to assess adverse‐events linked to psychoactive substances in children and adolescents

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims We sought to characterize adverse events and deaths associated with the use of psychoactive substances in children and adolescents. Methods Two French Addictovigilance databases were analysed: spontaneous reports and deaths over the period 2016–2021, in subjects aged 10–<18 years. An unsupervised classification was implemented on consumption data (
Hélène Peyrière   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy